Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve block shot could ease Long-COVID brain fog and fatigue?

NCT ID NCT07468604

Symptom relief Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if a nerve block injection in the neck can reduce long-COVID symptoms like fatigue, brain fog, and heart palpitations. About 78 adults with post-COVID condition will get either the real block or a fake injection to see if it helps. The goal is to find a safe, effective treatment for these lingering symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 78 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria 1. Age 18 years or older 2. PCC following COVID-19 infection with symptoms lasting for at least three months 3. Ability to read, write, and understand English 4. Quantified autonomic symptoms from at least one domain as reported by the patient on the screener Composite Autonomic Symptom Score (COMPASS-31), i.e. a COMPASS-31 score greater than 0. COMPASS-31 assesses 6 domains of autonomic symptoms: Orthostatic Intolerance, Vasomotor, Secretomotor, Gastrointestinal, Bladder, and Pupillomotor. 5. Patients should be stable on any PCC-related medications for at least four weeks. Exclusion criteria 1. History of co-existing conditions that are a contraindication for SGBCSBCSB: 1. Unilateral vocal cord paralysis; Severe chronic obstructive pulmonary disease (FEV1 between 30-50% of predicted value) 2. Recent myocardial infarction (within the last one year), Cardiac conduction block of any degree 3. Glaucoma 4. Infection or mass at injection site, bleeding disorders 2. Comorbid conditions that could confound study results, such as: 1. Active autoimmune disorders 2. Pre-existing autonomic dysfunction (e.g. POTS, IST, and CRPS) prior to COVID-19 3. Untreated psychiatric conditions (e.g. severe anxiety or PTSD requiring medication adjustments during the study period) 3. Recent history of major surgery or cerebrovascular events within the last three months 4. Allergy to local anesthetic; Inability to extend the neck for any reason (e.g. severe arthritis) 5. History of prior stellate ganglion block

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autonomic dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

post-COVID-19 disorder primary dysautonomia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autonomic dysfunction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Toronto Western Hospital

    RECRUITING

    Toronto, Ontario, M5T 2S8, Canada

  • Toronto Western Hospital/UHN

    RECRUITING

    Toronto, Ontario, Canada

  • Women's College Hospital

    NOT_YET_RECRUITING

    Toronto, Ontario, M5S 1B3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.